These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12732845)

  • 1. Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation.
    Carcillo JA; Adedoyin A; Burckart GJ; Frye RF; Venkataramanan R; Knoll C; Thummel K; Roskos L; Wilson JW; Sereika S; Romkes M; Bebia Z; Branch RA
    Clin Pharmacol Ther; 2003 May; 73(5):456-67. PubMed ID: 12732845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers.
    Carcillo JA; Parise RA; Adedoyin A; Frye R; Branch RA; Romkes M
    Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):149-159. PubMed ID: 8832907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
    Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
    Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
    Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
    McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A; de la Rubia A; Berecz R; Dorado P
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.
    Shimada T; Tsumura F; Yamazaki H; Guengerich FP; Inoue K
    Pharmacogenetics; 2001 Mar; 11(2):143-56. PubMed ID: 11266079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
    Haas CE; Brazeau D; Cloen D; Booker BM; Frerichs V; Zaranek C; Frye RF; Kufel T
    Eur J Clin Pharmacol; 2005 Sep; 61(8):583-93. PubMed ID: 16041547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
    Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT
    Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients.
    Bendriss A; Bechtel Y; Paintaud G; Bendriss EK; Joanne C; Bresson-Hadni S; Magnette J; Becker MC; Gillet M; Mantion G
    Ther Drug Monit; 1995 Apr; 17(2):113-9. PubMed ID: 7624897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Only truncated, not complete cytochrome p450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes.
    McConnachie LA; Phillips B; Bajpai M; Shen DD; Ho RJ
    Drug Metab Dispos; 2003 Sep; 31(9):1103-7. PubMed ID: 12920165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
    Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
    Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.